What question did this study set out to answer?

This analysis aims to evaluate the efficacy and safety of iptacopan in patients with paroxysmal nocturnal hemoglobinuria from a managed access program.

December 8, 2025Blood

Iptacopan monotherapy demonstrated improved clinical outcomes in a real-world cohort with paroxysmal nocturnal hemoglobinuria: Evidence from a managed access program

View Full Paper

Ask AI

Bookmark

Authors

SRS RizkMenoufia University TCTim CostiganNovartis (Switzerland)

Discussion

Member takes

Implication

Managed access program shows improved hemoglobin and treatment satisfaction in PNH patients, indicating potential benefits of iptacopan therapy.

Key Points

This analysis aims to evaluate the efficacy and safety of iptacopan in patients with paroxysmal nocturnal hemoglobinuria from a managed access program.
Evaluated patients with confirmed PNH in a managed access program for iptacopan treatment.
Collected data on hemoglobin, reticulocyte count, lactate dehydrogenase, and treatment satisfaction at baseline and retreatment visits.
Tracking adverse events during the treatment period.
Significant improvement in hemoglobin levels and treatment satisfaction observed at successive retreatment visits.
Reduction in blood transfusion visits and fatigue reported following treatment with iptacopan.
Safety profile consistent with findings from clinical trials with 39 cases reporting adverse events.

Cite This Study

Rizk et al. (2025) studied this question.

synapsesocial.com/papers/69362f444fa91c937236d5c1 https://doi.org/10.1182/blood-2025-3202

View Full Paper

Ask AI

Bookmark

Implication

Managed access program shows improved hemoglobin and treatment satisfaction in PNH patients, indicating potential benefits of iptacopan therapy.

Iptacopan monotherapy demonstrated improved clinical outcomes in a real-world cohort with paroxysmal nocturnal hemoglobinuria: Evidence from a managed access program

Discussion

Member takes

Implication

Key Points

Cite This Study

Iptacopan monotherapy demonstrated improved clinical outcomes in a real-world cohort with paroxysmal nocturnal hemoglobinuria: Evidence from a managed access program

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider